Wegovy vs Ozempic: Same Molecule, Different FDA Approvals — Evidence Review

This head-to-head evidence review is part of Weight Loss Rankings’ living editorial database — 300+ research articles and 190+ clinically-reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Wegovy and Ozempic are not different drugs in any pharmacological sense. They contain the same active molecule — semaglutide — manufactured by the same company, Novo Nordisk. What separates them are four regulatory and commercial wrappers: a different FDA- approved indication, a different maximum dose, a different pen design, and a different insurance-coverage reality. This article walks through each layer with the trial and FDA-label evidence behind it.

Same molecule — different drug names

The active ingredient in both products is semaglutide, a 31-amino-acid synthetic glucagon-like peptide-1 (GLP-1) receptor agonist analogue with a C18 fatty-diacid side chain that enables binding to circulating albumin and the once-weekly half-life. Both products are manufactured by Novo Nordisk at the same facilities, in the same single-use prefilled pen format, with the same excipient profile. The molecule in a Wegovy pen and the molecule in an Ozempic pen are chemically indistinguishable.

What differs are the FDA-approved indication, the FDA-approved dose ladder, and the FDA-approved maximum dose. Those three differences produce two distinct New Drug Application approvals and two distinct product labels even though the chemistry is identical.

FDA indications side-by-side

The FDA-approved indications drive how each product is prescribed, billed, and covered. Verbatim from the current DailyMed labels:

The cardiovascular language is the most important detail to read carefully. Both labels carry an MACE-reduction indication, but they are populations apart: Ozempic’s CV indication is for T2D plus established CV disease, anchored to the SUSTAIN-6 trial^[2]. Wegovy’s CV indication is for established CV disease plus overweight/obesity without diabetes, anchored to SELECT^[4]. A patient who has T2D plus established CV disease but is not obese is on-label for Ozempic but not for Wegovy; a patient with established CV disease plus obesity but no T2D is on-label for Wegovy but not for Ozempic.

Dosing schedules and titration

Both products use a slow titration to manage GI tolerability. The ladders differ in number of steps and in the maximum dose reached.

Wegovy dose ladder (5 steps to 2.4 mg):

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

Ozempic dose ladder (4 steps to 2.0 mg):

• Weeks 1-4: 0.25 mg once weekly (initiation; not therapeutic)
• Weeks 5 onward: 0.5 mg once weekly
• If glycemic control inadequate after 4+ weeks at 0.5 mg: increase to 1.0 mg
• If glycemic control inadequate after 4+ weeks at 1.0 mg: increase to 2.0 mg

Two practical consequences flow from this. First, Wegovy’s full titration to 2.4 mg takes 16 weeks — about four months — before the maintenance dose is reached. Patients shopping purely on the trial weight-loss numbers should expect a runway, not an overnight effect. Second, Ozempic’s ladder is prescriber-driven (intensify if glycemic control is inadequate) rather than time-driven (intensify automatically every 4 weeks). Many Ozempic patients sit at 0.5 mg or 1.0 mg long-term and never reach 2.0 mg, because their HbA1c target is met at a lower dose.

Trial data: STEP-1 (Wegovy) vs SUSTAIN program (Ozempic)

Wegovy and Ozempic ride on separate pivotal trial programs because they target separate FDA indications. STEP is the Wegovy weight-loss program; SUSTAIN is the Ozempic T2D glycemic-control program; SELECT is the cardiovascular-outcomes trial that crossed the two populations.

STEP-1: the Wegovy pivotal weight-loss trial

STEP-1 (Wilding et al., NEJM 2021) randomized 1,961 adults with overweight or obesity but without diabetes to once-weekly semaglutide 2.4 mg or placebo, with a lifestyle-intervention background, for 68 weeks. Mean body-weight reduction was −14.9% on semaglutide 2.4 mg vs −2.4% on placebo (treatment-regimen estimand). Approximately 32% of semaglutide-treated patients reached at least 20% body-weight reduction.^[1]

SUSTAIN: the Ozempic T2D program

SUSTAIN-1 (Sorli et al., Lancet Diabetes Endocrinol 2017) was the pivotal T2D monotherapy trial. Semaglutide 0.5 mg and 1.0 mg weekly produced mean HbA1c reductions of about −1.45% and −1.55% respectively at 30 weeks, with mean body-weight reductions of about −3.7 kg and −4.5 kg. SUSTAIN-6 (Marso et al., NEJM 2016) was the cardiovascular outcomes trial: in 3,297 adults with T2D at high CV risk, once-weekly semaglutide reduced the primary composite of CV death, nonfatal MI, or nonfatal stroke (HR 0.74, 95% CI 0.58–0.95, p<0.001 for non-inferiority, p=0.02 for superiority) over a median 2.1 years.^[3][2]

SELECT: the trial that bridged Wegovy into CV territory

SELECT (Lincoff et al., NEJM 2023) randomized 17,604 adults aged 45+ with established cardiovascular disease and overweight or obesity but without diabetes to semaglutide 2.4 mg weekly or placebo, with a median follow-up of 39.8 months. The primary MACE composite (CV death, nonfatal MI, nonfatal stroke) occurred in 6.5% of the semaglutide group vs 8.0% of placebo (HR 0.80, 95% CI 0.72–0.90, p<0.001). SELECT supported the 2024 FDA label expansion adding a cardiovascular indication to Wegovy.^[4]

FLOW: kidney outcomes evidence on the Ozempic side

FLOW (Perkovic et al., NEJM 2024) randomized 3,533 adults with T2D and chronic kidney disease to once-weekly semaglutide 1.0 mg or placebo and was stopped early for efficacy. The primary composite kidney outcome (major kidney disease event) occurred at HR 0.76 (95% CI 0.66–0.88) in favor of semaglutide. FLOW reinforces the Ozempic value proposition in T2D patients with CKD, where nephroprotection is a separate clinical lever from glycemic control.^[5]

Side effects: nearly identical, dose-scaled

Because the molecule is identical, the side-effect profile is identical in kind. What differs is the rate, which scales with dose. The dominant adverse events across both programs are the gastrointestinal class effects of GLP-1 receptor agonism: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and occasional eructation.

Pooled adverse-event rates from the pivotal trials at the highest labeled doses:

• Nausea: ~44% on Wegovy 2.4 mg (STEP-1) vs ~16% on placebo. Lower in absolute rate on Ozempic 1.0 mg (~16-20% across SUSTAIN trials). Most events are mild to moderate and cluster in the dose-escalation period.
• Vomiting: ~24% Wegovy vs ~8% placebo in STEP-1. ~8-9% on Ozempic 1.0 mg in SUSTAIN trials.
• Diarrhea: ~30% Wegovy vs ~16% placebo. ~9-11% on Ozempic 1.0 mg.
• Constipation: ~24% Wegovy vs ~11% placebo. ~5-7% on Ozempic 1.0 mg.
• Discontinuation for adverse events: 7.0% on Wegovy 2.4 mg vs 3.1% on placebo (STEP-1).

The rate differential between Wegovy and Ozempic at maximum dose is primarily a dose effect, not a different drug effect. The 2.4 mg dose pushes the GLP-1 receptor harder than 1.0 mg or 2.0 mg, and more GLP-1 agonism produces more GI symptoms. A patient who tolerates Ozempic 1.0 mg well will not necessarily tolerate Wegovy 2.4 mg as comfortably — the maintenance dose is higher.

Both labels carry the FDA boxed warning for risk of thyroid C-cell tumors, based on rodent carcinogenicity studies. Both labels contraindicate use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both labels carry warnings for acute pancreatitis, acute gallbladder disease, hypoglycemia (especially when combined with insulin or sulfonylureas), acute kidney injury secondary to dehydration from GI losses, diabetic retinopathy complications in T2D, and suicidal behavior/ideation (post-marketing surveillance).

Cost and insurance coverage in 2026

Cash pricing and insurance coverage are where the two FDA labels diverge most sharply in practice.

Cash-pay pricing through NovoCare

Novo Nordisk operates a self-pay program called NovoCare Pharmacy for patients who pay out of pocket. As of May 2026:

• Wegovy (all doses): $499/month for a 28-day supply through NovoCare Pharmacy direct-pay, available at the maintenance 2.4 mg dose and at all titration steps below it.^[10]
• Ozempic (all doses): $499/month for self-pay patients via the NovoCare Pharmacy channel. Patients pay the same flat cash price whether they fill 0.25 mg, 0.5 mg, 1.0 mg, or 2.0 mg pens.^[10]
• Retail list (WAC) without NovoCare: Both products list near $1,349/month at full retail before insurance or manufacturer discount programs.

Insurance coverage: where the two labels diverge

For commercial insurance plans, Ozempic is generally more widely covered than Wegovy because T2D coverage is mandated more consistently across formularies than chronic weight management coverage:

• Ozempic for T2D: Covered on most commercial formularies as tier-2 or tier-3, typically with quantity limits and sometimes step therapy after metformin. Medicare Part D plans cover Ozempic when prescribed for T2D and, since 2024 CMS guidance, when prescribed for the SUSTAIN-6 cardiovascular indication in T2D patients with established CV disease.
• Wegovy for chronic weight management: Coverage is much narrower. Many commercial plans exclude anti-obesity medications entirely; plans that do cover require BMI documentation, comorbidity documentation, prior authorization, and frequently step therapy (failed lifestyle intervention or failed phentermine). Medicare does not cover anti-obesity drugs by statute, so Wegovy is not covered under Medicare Part D when prescribed for chronic weight management. However: following the 2024 Wegovy CV indication expansion, Medicare Part D plans have begun covering Wegovy when prescribed for cardiovascular risk reduction in adults with established CV disease and obesity — the CV indication routes around the anti-obesity-drug statutory exclusion.

The compounded alternative is no longer the workaround it was

Through 2024 and into early 2025, the FDA drug-shortage list included semaglutide, which authorized 503A pharmacies to compound the molecule for individual patients under the FDA’s compounding-during-shortage policy. In February 2025 the FDA formally declared the shortage resolved, and the regulatory window for routine compounded semaglutide closed. Compounded semaglutide remains available through some 503A pharmacies under personalized prescription pathways (specific medical-necessity justifications, allergy-driven substitutions), but it is no longer the broad cash-pay workaround it was during the shortage. For the legal and clinical landscape post-shortage, see Wegovy alternatives in 2026.

When prescribers pick Ozempic vs Wegovy

Working through the FDA indications, the trial data, and the coverage reality, the choice between Wegovy and Ozempic tends to sort cleanly into patient profiles:

• Type 2 diabetes plus weight to lose: Ozempic. On-label for glycemic control, broader insurance coverage, and weight loss as a meaningful secondary effect at 1.0 mg or 2.0 mg weekly. The patient who would have started metformin alone gets metformin + Ozempic and treats both axes with one weekly injection.
• Obesity without T2D, no established CV disease: Wegovy. On-label for chronic weight management; the 2.4 mg dose is what STEP-1 measured the −14.9% body-weight reduction against; off-label Ozempic use will face routine insurance denials for weight management.
• Obesity plus established CV disease, no T2D: Wegovy. The SELECT-supported cardiovascular indication makes Wegovy on-label for this population specifically, and Medicare Part D now covers Wegovy under this indication when prescribed for CV risk reduction.
• T2D plus established CV disease: Ozempic. The SUSTAIN-6-supported cardiovascular indication is exactly this population, and the broader T2D formulary coverage makes the access path easier than Wegovy.
• T2D plus chronic kidney disease: Ozempic. FLOW showed a 24% relative reduction in the composite kidney outcome, giving Ozempic a nephroprotection lever that Wegovy’s label does not currently carry.^[5]
• Patient already on Ozempic 1.0 or 2.0 mg who wants maximum weight loss: Switch to Wegovy. Continue the titration ladder to 2.4 mg; expect a 4-8 week tolerability check at the higher dose; insurance may require a new prior auth under the chronic weight management indication.

For a wider lens that also compares semaglutide against tirzepatide (Zepbound, Mounjaro) and orforglipron (Foundayo), see the tirzepatide vs semaglutide head-to-head review and the full GLP-1 medication reference. For the broader category of injectable GLP-1 options including liraglutide (Saxenda, Victoza), see the weight-loss injections guide.

Bottom line

• Same molecule, different labels. Wegovy and Ozempic both contain semaglutide. The only material differences are the FDA-approved indication, the maximum dose (2.4 mg vs 2.0 mg weekly), and the resulting insurance and access landscape.
• Wegovy for weight, Ozempic for diabetes — with cardiovascular wrinkles. Both labels now carry a cardiovascular risk-reduction indication, but for different populations: SUSTAIN-6 anchors Ozempic in T2D + CV disease; SELECT anchors Wegovy in obesity + CV disease without T2D.
• Side effects scale with dose, not with brand. Higher Wegovy nausea rates reflect the higher 2.4 mg maintenance dose, not a different molecule. Both labels carry the same boxed warnings.
• Cost is similar; coverage is not. Both list $499/month self-pay through NovoCare Pharmacy and near $1,349/month retail. Ozempic is more widely covered by insurance because T2D is more universally a covered condition than chronic weight management.
• Switching between the two is straightforward. Same molecule means no washout. Re-titrate to the closest matching dose step on the destination label and re-check tolerability at the higher Wegovy maintenance dose.

Frequently asked questions

Related research

• Tirzepatide vs semaglutide head-to-head review — extends this comparison across drug classes; SURMOUNT-5 head-to-head trial data and the cost-per-pound calculation.
• Full GLP-1 medication list reference — every FDA-approved GLP-1 with brand, manufacturer, indication, dose ladder, and DailyMed SetID links.
• Weight-loss injections guide — the broader category of injectable GLP-1 options, including Saxenda and Zepbound.
• What SELECT showed about semaglutide and heart attack risk — the trial that gave Wegovy its 2024 cardiovascular indication.
• Wegovy alternatives in 2026 — the post-shortage landscape for patients who cannot access brand Wegovy.
• Wegovy drug profile — full label, dose ladder, side-effect rates, and provider availability.
• Ozempic drug profile — full label, dose ladder, side-effect rates, and provider availability.

Important disclaimer. This article is educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Wegovy and Ozempic are prescription medications with boxed warnings and contraindications; every clinical decision involving either drug must be made with a licensed prescriber who has reviewed the full FDA prescribing information and the individual patient’s history. Every regulatory claim in this article is anchored to a primary source (DailyMed or PubMed). Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.